Double revenues for biotech startup Abc biopply

Sustainability and the reduction of animal testing are a topic of discussion in the life sciences sector. Based in Solothurn with laboratory and research facilities in Cham, abc biopply, a contract research organisation founded in 2018, sought to address this issue while improving and supporting the transition from scientific research to clinical applications. The company has developed the CoSeedis platform, a proprietary 3D technology platform to speed up drug discovery processes and make preclinical studies faster and more predictive.

Using the 3D CoSeedis assays, customers analyse important parameters – such as pharmacology, pharmacokinetics and toxicology – at a fast pace, cost-efficiently and under native conditions. Because the model generates hundreds of identical spheroids per measured data point in a single step, it provides unique predictiveness and consequently reduces the use of animals to a minimum. The 3D CoSeedis Preclinical Study Cycle has originally been developed for solid tumours. However, the company is currently validating the 3D model also for various neurological applications.

Leading pharmaceutical companies worldwide already rely on the validated assay portfolio that was launched in 2019. With the majority of customers based in Switzerland, abc biopply has been expanding in other regions. Within Europe, it serves most customers in Germany and in Asia customers are located in Japan, Korea and most recently in Singapore. Moving forward, the startups sees growth potential in the US and Chinese markets  

Thanks to the growing customer base, the company has seen a two-factor growth in revenues reaching in 2021, reaching 236%. The company also boasts of having a team of six employees. For the year 2022, abc biopply expects a further expansion of its market success. The demand for the services offered continues unchanged and numerous new project contracts are about to be signed.

(Press release/RAN)